We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120 as a treatment for anxiety.

The primary endpoint of the Panorama study is the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 ODT 100 µg versus placebo. MindMed's Chief Medical ...

Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide D-tartrate (LSD), MM120 orally disintegrating tablets (ODT), for the ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a clinical-stage biopharma company focused on creating new treatments for brain health disorders and stands eighth among the 12 best psychedelic ...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders ...

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for ...

The Panorama study will evaluate the efficacy and safety of MM120 ODT versus placebo, will be conducted in the United States and Europe, and is expected to enroll approximately 250 participants. "This ...